Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BridgeBio Pharma Inc.

bridgebio.com

Latest From BridgeBio Pharma Inc.

Finance Watch: Three New Biopharma IPOs In The US With Eight More Entering The Queue

Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.

Financing Business Strategies

ElevateBio Brings Centralized Model To Cell And Gene Therapy

The company run by former Alexion and bluebird executives raised $150m and will build an R&D and manufacturing facility to serve its own start-ups and strategic partners, centralizing capabilities that would take individual firms millions of dollars and years to develop for a single product.

Financing StartUps and SMEs

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Rare Diseases Pricing Strategies

Rare Disease Roundtable: How Rare Is Too Rare?

Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.

Rare Diseases Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register